The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis
Open accessAbstract
Importance: Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials. Objective: To evaluate whether baseline LDL-C level is associated with total and cardiovascular mortality risk reductions. Data Sourcesand Study Selection: Electronic databases (Cochrane, MEDLINE, EMBASE, TCTMD, ClinicalTrials.gov, major congress proceedings) were searched through February 2, 2018, to identify randomized clinical trials of statins, ezetimibe, and PCSK9-inhibiting monoclonal antibodies. Data Extraction and Synthesis: Two investigators abstracted data and appraised risks of bias. Intervention groups were categorized as "more intensive" (more potent pharmacologic intervention) or "less intensive" (less potent, placebo, or control group). Main Outcomes and Measures: The coprimary end points were total mortality and cardiovascular mortality. Random-effects meta-regression and meta-analyses evaluated associations between baseline LDL-C level and reductions in mortality end points and secondary end points including major adverse cardiac events (MACE). Results: In 34 trials, 136 299 patients received more intensive and 133 989 received less intensive LDL-C lowering. All-cause mortality was lower for more vs less intensive therapy (7.08% vs 7.70%; rate ratio [RR], 0.92 [95% CI, 0.88 to 0.96]), but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with greater reductions in all-cause mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.91 [95% CI, 0.86 to 0.96]; P = .001; absolute risk difference [ARD], -1.05 incident cases per 1000 person-years [95% CI, -1.59 to -0.51]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Cardiovascular mortality was lower for more vs less intensive therapy (3.48% vs 4.07%; RR, 0.84 [95% CI, 0.79 to 0.89]) but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with a greater reduction in cardiovascular mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.86 [95% CI, 0.80 to 0.94]; P < .001; ARD, -1.0 incident cases per 1000 person-years [95% CI, -1.51 to -0.45]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Trials with baseline LDL-C levels of 160 mg/dL or greater had the greatest reduction in all-cause mortality (RR, 0.72 [95% CI, 0.62 to 0.84]; P < .001; 4.3 fewer deaths per 1000 person-years) in a meta-analysis. More intensive LDL-C lowering was also associated with progressively greater risk reductions with higher baseline LDL-C level for myocardial infarction, revascularization, and MACE. Conclusions and Relevance: In these meta-analyses and meta-regressions, more intensive compared with less intensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels. This association was not present when baseline LDL-C level was less than 100 mg/dL, suggesting that the greatest benefit from LDL-C-lowering therapy may occur for patients with higher baseline LDL-C levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is an independent risk factor for CHD (3–5).”
From Remnant cholesterol, lipid ratios, and the severity of coronary artery lesions: a retrospective cohort study in patients with coronary heart disease (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Flagged first, then by citations
2 of the 58 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- TiceJA; Institute for Clincal and Economic Review (ICER). Evolocumab for treatment of high cholesterol: clinical effectiveness: new evidence update. Institute for Clincal and Economic Review website. https://icer-review.org/material/pcks9-inhibitors-neu/. June 13, 2017. Accessed March 16, 2018.
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 507
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 440
PCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338
Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
Michos, E. D., McEvoy, J. W., & Blumenthal, R. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806939 · Cited by 354
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · Figshare · Cited by 337
Ballantyne, C. M., Laufs, U., Ray, K. K., Leiter, L. A., Bays, H. E., Goldberg, A. C., Stroes, E. S., MacDougall, D., Zhao, X., & Catapano, A. L. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319864671 · Cited by 358
Cardiovascular disease and cancer: shared risk factors and mechanisms
Wilcox, N. S., Amit, U., Reibel, J. B., Berlin, E. E., Howell, K., & Ky, B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01017-x · Cited by 342
High lipoprotein(a) and high risk of mortality
Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy902 · Cited by 288
Chou, R., Cantor, A., Dana, T., Wagner, J., Ahmed, A. Y., Fu, R., & Ferencik, M. (2022) · JAMA · doi:10.1001/jama.2022.12138 · Cited by 287
Johannesen, C. D. L., Langsted, A., Mortensen, M. B., & Nordestgaard, B. G. (2020) · BMJ · doi:10.1136/bmj.m4266 · Cited by 259
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Damask, A., Steg, P. G., Schwartz, G. G., Szarek, M. J., Hagström, E., Badimón, L., Chapman, M. J., Boileau, C., Tsimikas, S., Ginsberg, H. N., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.044434 · Cited by 241
2023 Chinese guideline for lipid management
Li, J., Zhao, S., Zhao, D. H., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 241
Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage
Ma, C., Gurol, M. E., Huang, Z., Lichtenstein, A. H., Wang, X., Wang, Y., Neumann, S., Wu, S., & Gao, X. (2019) · Neurology · doi:10.1212/wnl.0000000000007853 · Cited by 199
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187
Schubert, J. R., Lindahl, B., Melhus, H., Renlund, H., Leósdóttir, M., Yari, A., Ueda, P., James, S. K., Reading, S. R., Dluzniewski, P. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1011 · Cited by 193
Navarese, E. P., Lansky, A. J., Kereiakes, D. J., Kubica, J., Gurbel, P. A., Gorog, D. A., Valgimigli, M., Curzen, N. P., Kandzari, D. E., Bonaca, M. P., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab246 · Cited by 157
Self-citationKhan, S. U., Yedlapati, S. H., Lone, A. N., Hao, Q., Guyatt, G., Delvaux, N., Bekkering, G. E. (., Vandvik, P. O., Riaz, I. B., Li, S., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069116 · Cited by 151
Effect of Alirocumab on Mortality After Acute Coronary Syndromes
Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Brégeault, M.-F., Dalby, A. J., Díaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038840 · Cited by 153
Khan, S. U., Khan, M. Z., Subramanian, C. R., Riaz, H., Khan, M. U., Lone, A. N., Khan, M. S., Benson, E., Alkhouli, M. A., Blaha, M. J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.5202 · Cited by 142
Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care
Watts, G. F., Gidding, S. S., Mata, P., Pang, J., SULLIVAN, D. R., Yamashita, S., Raal, F. J., Santos, R. D., & Ray, K. K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0325-8 · Cited by 144
Poli, A., Barbagallo, C. M., Cicero, A. F. G., Corsini, A., Manzato, E., Trimarco, B., Bernini, F., Visioli, F., Bianchi, A., Canzone, G., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.05.015 · Cited by 134
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 120
Navarese, E. P., Vine, D., Proctor, S., Grzelakowska, K., Berti, S., Kubica, J., & Raggi, P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.123.319297 · Cited by 107
Self-citationChinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 109
Bioactive compounds from herbal medicines to manage dyslipidemia
Ji, X., Shi, S., Liu, B., Shan, M., Tang, D., Zhang, W., Zhang, Y., Zhang, L., Zhang, H., Lu, C. C., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109338 · Cited by 107
Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem
Gidding, S. S., & Allen, N. B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012924 · Cited by 109
Rea, F., Biffi, A., Ronco, R., Franchi, M., Cammarota, S., Citarella, A., Conti, V., Filippelli, A., Sellitto, C., & Corrao, G. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.13186 · Cited by 97
Observational study of the medical management of patients with peripheral artery disease
Saratzis, A. N., Jaspers, N. E. M., Gwilym, B. L., Thomas, O., Tsui, A., Lefroy, R., Parks, M., Htun, Mera, Z., Thatcher, A. J., et al. (2019) · British journal of surgery · doi:10.1002/bjs.11214 · Cited by 87
Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83
Rong, S., Li, B., Chen, L., Sun, Y., Du, Y., Liu, B., Robinson, J. G., & Bao, W. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023690 · Cited by 88
Self-citationLow-Density Lipoprotein Cholesterol, Cardiovascular Disease Risk, and Mortality in China
Chen, L., Chen, S., Bai, X., Su, M., He, L., Li, G., He, G., Yang, Y., Zhang, X., Cui, J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.22558 · Cited by 83
Duell, P. B., Gidding, S. S., Andersen, R. L., Knickelbine, T., Anderson, L., Gianos, E., Shrader, P. J., Kindt, I., O'Brien, E. C., McCann, D., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.007 · Cited by 81
Eichelmann, F., Prada, M., Sellem, L., Jackson, K. G., Salas‐Salvadó, J., Razquín, C., Estruch, R., Friedén, M., Rosqvist, F., Risérus, U., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03124-1 · Cited by 92
Fan, J., Liu, Y., Yin, S., Chen, N., Bai, X., Ke, Q., Shen, J., & Xia, M. (2019) · Nutrition & Metabolism · doi:10.1186/s12986-019-0334-y · Cited by 74
Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease
Nielsen, J. B., Rom, O., Surakka, I. L., Graham, S. E., Zhou, W., Roychowdhury, T., Fritsche, L. G., Taliun, S. A. G., Sidore, C., Liu, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20086-3 · Cited by 70
Khan, S. U., Rahman, H., Okunrintemi, V., Riaz, H., Khan, M. S., Sattur, S., Kaluski, E., Lincoff, A. M., Martin, S. S., & Blaha, M. J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011581 · Cited by 70
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Ma, R., Qi, Y., Zhao, X., Li, X., Sun, X., Niu, P., Li, Y., Guo, C., Chen, R., & Sun, Z. (2020) · Particle and Fibre Toxicology · doi:10.1186/s12989-020-00380-0 · Cited by 68
Zhao, X., Wang, D., & Qin, L. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01835-0 · Cited by 68
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes
Bhatt, D. L., Briggs, A. H., Reed, S. D., Annemans, L., Szarek, M. J., Bittner, V., Díaz, R., Goodman, S. G., Harrington, R. A., Higuchi, K., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.029 · Cited by 63
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
Mourikis, P., Zako, S., Dannenberg, L., Nia, A. M., Heinen, Y., Busch, L., Richter, H., Hohlfeld, T., Zeus, T., Kelm, M., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107592 · Cited by 60
Hamilton, F., Hughes, D. A., Spiller, W., Tilling, K. M., & Smith, G. D. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-024-01113-9 · Cited by 61
Associations of remnant cholesterol with cardiovascular and cancer mortality in a nationwide cohort
Tian, Y., Wu, Y., Qi, M., Song, L., Chen, B., Wang, C., Lu, J., Yang, Y., Zhang, X., Cui, J., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.12.035 · Cited by 59
Robinson, J. G., Jayanna, M. B., Brown, A. S., Aspry, K. E., Orringer, C. E., Gill, E. A., Goldberg, A. C., Jones, L. K., Maki, K. C., Dixon, D. L., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.005 · Cited by 57
Self-citationB vitamins for stroke prevention
Hankey, G. J. (2018) · Stroke and Vascular Neurology · doi:10.1136/svn-2018-000156 · Cited by 54
A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update
Li, H., Wu, X., Xu, A., & Hoo, R. L. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179386 · Cited by 57
Xie, H., Luo, X., Gao, Y., Huang, M. Z., Ren, G., Zhou, R., Sun, Y., Ye, H. L., Lei, Q., Fang, W., et al. (2024) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2024.109768 · Cited by 53
Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets
Xia, Y., Gao, D., Wang, X., Liu, B., Shan, X., Sun, Y., & Ma, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1331609 · Cited by 58
Wang, Z., Wu, M., Du, R., Tang, F., Xu, M., Gu, T., & Yang, Q.-C. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02171-4 · Cited by 50
Management of Blood Cholesterol
Alenghat, F. J., & Davis, A. M. (2019) · JAMA · doi:10.1001/jama.2019.0015 · Cited by 50
Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis
Nayak, A., Hayen, A. D., Zhu, L., McGeechan, K., Glasziou, P., Irwig, L., Doust, J. A., Gregory, G. A., & Bell, K. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020584 · Cited by 53
Qiu, J., Kong, X., Li, J., Yang, J., Huang, Y., Huang, M.-S., Sun, B., Su, J., Chen, H., Wan, G.-B., et al. (2021) · Journal of Neural Transplantation and Plasticity · doi:10.1155/2021/6627507 · Cited by 44
Cancer and Cardiovascular Disease
Alhuneafat, L., Guha, A., Blaes, A. H., & Konety, S. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.07.001 · Cited by 55
Pivonello, R., Zacharieva, S., Elenkova, A. P., Tóth, M., Shimon, I., Stigliano, A., Badiu, C., Brue, T. C., Georgescu, C. E., Tsagarakis, S., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01263-7 · Cited by 48
Zhong, W., Fu, C., Xu, L., Sun, X., Wang, S., He, C., & Wei, Q. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03120-2 · Cited by 56
Nakano, T., Inoue, I., & Murakoshi, T. (2019) · Nutrients · doi:10.3390/nu11020310 · Cited by 48
Kohli-Lynch, C. N., Bellows, B. K., Thanassoulis, G., Zhang, Y., Pletcher, M. J., Vittinghoff, E., Pencina, M. J., Kazi, D. S., Sniderman, A. D., & Moran, A. E. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.2851 · Cited by 47
Chen, Z., Gu, H., Mo, J., Yang, K., Jiang, Y., Yang, X., Wang, C., Xu, J., Meng, X., Jiang, Y., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.05.028 · Cited by 47
Zhang, B., & Schmidlin, T. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00028-z · Cited by 48
Inclisiran in lipid management: A Literature overview and future perspectives
Scicchitano, P., Milo, M., Mallamaci, R., Palo, M. D., Caldarola, P., Massari, F., Gabrielli, D., Colivicchi, F., & Ciccone, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112227 · Cited by 47
PCSK9 inhibitors and cardiovascular outcomes
Steffens, D., Bramlage, P., Scheeff, C., Kašner, M., Hassanein, A., Friebel, J., & Rauch‐Kröhnert, U. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677604 · Cited by 46
Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 43
The Effect of Helicobacter pylori Eradication on Lipid Levels: A Meta-Analysis
Watanabe, J., Hamasaki, M., & Kotani, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050904 · Cited by 42
Association between Air Pollution and Lipid Profiles
Zhang, Y., Shi, J., Ma, Y., Yu, N., Zheng, P., Chen, Z., Wang, T., & Jia, G. (2023) · Toxics · doi:10.3390/toxics11110894 · Cited by 42
Nanna, M. G., Návar, A. M., WOJDYLA, D. M., & Peterson, E. D. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16123 · Cited by 42
Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies
Santos, H. O., KONES, R. J., Rumana, U., Earnest, C. P., Izidoro, L. F. M., & Macedo, R. C. O. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.06.002 · Cited by 42
Kawamoto, R., Kikuchi, A., Akase, T., Ninomiya, D., & Kumagi, T. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01533-6 · Cited by 39
Yang, L., Yue, Q., Fang, F., Zhang, Y., Liu, P., Zhang, Z., Wang, G., Chen, S., Wu, S., & Yang, X. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01826-3 · Cited by 39
Strategies to Overcome Residual Risk During Statins Era
Cho, K. I., Yu, J., Hayashi, T., Han, S. H., & Koh, K. K. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0624 · Cited by 39
Lee, K. H., Jeong, E.-S., Jang, G., Na, J.-R., Park, S., Kang, W. S., Kim, E. S., Choi, H., Kim, J. S., & Kim, S. (2020) · Nutrients · doi:10.3390/nu12030610 · Cited by 39
Lin, Y., Parco, C., Karathanos, A., Krieger, T., Schulze, V., Chernyak, N., Icks, A., Kelm, M., Brockmeyer, M., & Wolff, G. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-048893 · Cited by 38
Ma, X., Bai, Y., Liu, K., Han, Y., Zhang, J., Liu, Y., Hou, X., Hao, E., Hou, Y., & Bai, G. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154233 · Cited by 39
Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal
Ngo‐Metzger, Q., Zuvekas, S. H., Shafer, P. R., Tracer, H. L., Borsky, A. E., & Bierman, A. S. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.06.180313 · Cited by 36
Bempedoic acid for the treatment of dyslipidemia
Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-6-5 · Cited by 36
Luca, L. D., Arca, M., Temporelli, P. L., Meessen, J. M. T. A., Riccio, C., Bonomo, P., Colavita, A. R., Gabrielli, D., Gulizia, M. M., & Colivicchi, F. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.05.055 · Cited by 36
Perrone, M. A., Feola, A., Pieri, M., Donatucci, B., Salimei, C., Lombardo, M., Perrone, A., & Parisi, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168858 · Cited by 43
Han, M., Huang, K., Shen, C., Hu, H., Liu, F., Li, J., Yang, X., Chen, J.-C., Liu, X., Cao, J., et al. (2024) · Stroke · doi:10.1161/strokeaha.124.046811 · Cited by 37
Zeng, G., Zhang, C., Song, Y., Zhang, Z., Xu, J., Liu, Z., Tang, X., Wang, X., Chen, Y., Zhang, Y., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03823-z · Cited by 38
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Rossi, M., Fabris, E., Barbisan, D., Massa, L., & Sinagra, G. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00497-3 · Cited by 35
Hua, J., Qiao, Y., Ke, C., & Shen, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-72601-7 · Cited by 34
Low‐density lipoprotein cholesterol and lifespan: A Mendelian randomization study
Daghlas, I., & Gill, D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14811 · Cited by 34
Langsted, A., & Nordestgaard, B. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000681 · Cited by 33
Possible mechanisms of cholesterol elevation aggravating COVID-19
Tang, Y., Hu, L., Liu, Y., Zhou, B., Qin, X., Ye, J., Shen, M., Wu, Z., & Zhang, P. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.62021 · Cited by 33
Tian, X., Zhang, N., Tse, G., Li, G., Sun, Y., & Liu, T. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae031 · Cited by 33
Zhang, Y., Yan, C., Dong, Y., Zhao, J., Yang, X., Deng, Y., Su, L., Yin, J., Zhang, Y., Sun, F., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.011 · Cited by 34
Talic, S., Marquina, C., Ofori‐Asenso, R., Petrova, M., Liew, D., Owen, A. J., Lybrand, S., Thomson, D., Ilomäki, J., Zomer, E., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07199-7 · Cited by 34
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 31
Strilchuk, L. M., Tocci, G., Fogacci, F., & Cicero, A. F. G. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1714028 · Cited by 31
Mousavi, S. M., Zargarzadeh, N., Rigi, S., Persad, E., Pizarro, A. B., Hasani‐Ranjbar, S., Larijani, B. A., Willett, W. C., & Esmaillzadeh, A. (2022) · Advances in Nutrition · doi:10.1093/advances/nmac040 · Cited by 31
Zuo, S., Wang, G., Han, Q., Xiao, H., Santos, H. O., Rodriguez, D. A., Khani, V., & Tang, J. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102450 · Cited by 29
Hsu, H., Lin, C., Lee, Y.-S., Wu, T., & Chien, K. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01567-1 · Cited by 30
Centralized and Federated Models for the Analysis of Clinical Data
Li, R., Romano, J. D., Chen, Y., & Moore, J. H. (2024) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-122220-115746 · Cited by 29
Vicente-Valor, J., García‐González, X., Ibáñez-García, S., Durán-García, M. E., de Lorenzo‐Pinto, A., Rodríguez, C., Méndez, I., Percovich-Hualpa, J. C., Alonso, A. H., & Sanjurjo‐Sáez, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112519 · Cited by 29
Metadata
- Authors
- Navarese, E. P., Robinson, J. G., Kowalewski, M., Kolodziejczak, M., Andreotti, F., Bliden, K., Tantry, U., Kubica, J., Raggi, P., & Gurbel, P. A.
- Affiliations
- Inova Health System (US)
- University of Iowa (US)
- Antoni Jurasz University Hospital (PL)
- Systematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE Cardiovascular Research Network
- Università Cattolica del Sacro Cuore (IT)
- Nicolaus Copernicus University (PL)
- University of Alberta (CA)
- Corresponding author
- Robinson, Jennifer G.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2018-04-17
- Volume
- 319
- Issue
- 15
- Pages
- 1566
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5933331
- OpenAlex
- W2800876320
- Semantic Scholar
- e998030b0bef031f54619a07cde9f01df4ce9807
- Cited by
- 549
- References
- 58
- Citations by year
- 2026: 36 · 2025: 74 · 2024: 81 · 2023: 70 · 2022: 56 · 2021: 76 · 2020: 62 · 2019: 68 · 2018: 26
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- LDL cholesterol, LDL cholesterol lowering, statins, ezetimibe, PCSK9 inhibitors, all-cause mortality, cardiovascular mortality, major adverse cardiac events, lipid-lowering therapy, dose-response relationship, treatment intensity, risk stratification, randomized controlled trials, meta-regression, risk of bias assessment, risk difference, relative risk, number needed to harm
- MeSH terms
- Ezetimibe, Proprotein Convertase 9, PCSK9 Inhibitors, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Mortality, Regression Analysis, Risk, Confounding Factors, Epidemiologic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
